Midatech Pharma PLC Official Opening of New Cardiff Headquarters
16 Setembro 2021 - 12:59PM
RNS Non-Regulatory
TIDMMTPH
Midatech Pharma PLC
16 September 2021
REACH
16 September 2021
Midatech Pharma PLC
("Midatech" or the "Company")
Official Opening of New Cardiff Headquarters
Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery
technology company focused on improving the bio-delivery and
biodistribution of medicines, is pleased to announce the formal
opening today of its new headquarters, incorporating purpose built
laboratory facilities and offices at 1 Caspian Point in Cardiff,
UK.
The Company has moved to the 1 Caspian Point building, part of
the Parmer Cardiff campus on the city's waterfront, where it has
created 8,050 sq ft of offices and laboratories on the ground and
first floors. This new headquarters provides bespoke accommodation
to facilitate the Company's future plans, particularly with its
programmes ustilising its Q-Sphera 3D printing technology to
encapsulate medicines in bio-degradable polymers for improved
delivery and targeting.
Stephen Stamp, Chief Executive Officer of Midatech, said: "Our
technology is unique and patented and we have identified a strategy
to work on multiple Q-Sphera programmes simultaneously and partner
them at an early stage.
"To execute on that plan Midatech needed expanded,
purpose-designed labs, as our previous facilities were far from
ideal with labs split over two floors and difficulties moving
materials and equipment in and out. The new premises at Caspian
Point have achieved this without a material increase in our costs
and are modern, 50 per cent larger, and much more usable, with a
layout tailored to suit our needs exactly, with capacity for
further expansion."
Vaughan Gething MS, Welsh Government Minister for the Economy,
when officially opening the new Midatech headquarters said: "Our
ambition is for Wales to be a global leader in Life Sciences,
whilst stimulating economic growth and creating new high-skilled
jobs. We are already able to provide the right environment for
companies to innovate and grow and, working alongside the NHS,
together we can tackle the greatest healthcare challenges of our
generation and address health inequalities. I'm very pleased to see
how this business has grown and will play an important part in
Wales' expanding Life Sciences sector."
For more information, please contact:
Midatech Pharma PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)29 2048 0180
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Joint
Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Tel: +44 (0)20 7886 2500
Turner Pope Investments (TPI) Limited (Joint Broker)
Andrew Thacker / James Pope (Corporate Broking)
Tel: +44(0)20 3657 0050
IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk
Edison Group (US Investor Relations)
Maxwell Colbert
Tel: +1 (646) 653 7028
Email: mcolbert@edisongroup.com
About Midatech Pharma PLC
Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ:
MTP) is a drug delivery technology company focused on improving
the bio-delivery and bio-distribution of medicines. The Company
combines approved and development medications with its proprietary
and innovative drug delivery technologies to provide compelling
products that have the potential to powerfully impact the
lives of patients.
The Company has developed three in-house technology platforms,
each with its own unique mechanism to improve delivery of
medications to sites of disease. All of the Company's technologies
have successfully entered human use in the clinic, providing
important validation of the potential for each platform:
* Q-Sphera(TM) platform: a disruptive micro-technology
used for sustained release to prolong and control the
release of therapeutics over an extended period of
time (from weeks to months).
* MidaSolve(TM) platform: an innovative nanotechnology
used to dissolve insoluble drugs so that they can be
administered in liquid form directly and locally into
tumours.
* MidaCore(TM) platform: a leading-edge nanotechnology
used for targeting medications to sites of disease.
The platform nature of the technologies offers the potential
to develop multiple drug assets rather than being reliant
on a limited number of programmes. Midatech's technologies
are supported by 36 patent families including 120 granted
patents and an additional 70 patent applications. Midatech's
headquarters and R&D facility is in Cardiff, UK. For more
information please visit www.midatechpharma.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASFFFIMEFSEDU
(END) Dow Jones Newswires
September 16, 2021 11:59 ET (15:59 GMT)
Midatech Pharma (LSE:MTPH)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Midatech Pharma (LSE:MTPH)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024